AIFA has published the new Guidelines for compiling the Dossier to Support the Health Technology Assessment (HTA) of a medicinal product for reimbursement and pricing
The Pharma Value team participated in ISPOR Europe 2024, held in Barcelona from 17 to 20 November. Under the theme 'Generating Evidence Toward Health and
The series of Nomos and Pharma Value specials regarding the governance of the Medicine and its Agency continues. After the seven extensions of the AIFA
The analysis addresses differences in regional access times for drug reimbursement in Italy. Following the official publication for drug reimbursement in the Gazzetta Ufficiale, the
The poster addresses the evolution of the utilisation of the AIFA 5% Fund, established in 2003 for the acquisition of orphan drugs and the treatment
On December 14th, 2022, a draft of the interministerial decree for the new AIFA regulation was shared by 'Quotidiano Sanità,' and on September 29th, what
For our colleagues outside Italy who watch us with attention and amazement, we are here to translate for you what is happening in Italy. For
This is our English version of the analysis 'Towards the reform of governance of the Italian Medicines Agency and the Single Committee' produced in collaboration
The Fund 5% for rare diseases, which allows access to medicines which do not have a MA in Italy, and which represent a hope of
On 30 December 2020 AIFA approved the document containing the provisions required by art. 2 of Ministerial Decree of 2 August 2019, 'Criteria and procedures
